EMAIL THIS PAGE TO A FRIEND

Pain

Early transcutaneous electrical nerve stimulation reduces hyperalgesia and decreases activation of spinal glial cells in mice with neuropathic pain.


PMID 25010326

Abstract

Although transcutaneous electrical nerve stimulation (TENS) is widely used for the treatment of neuropathic pain, its effectiveness and mechanism of action in reducing neuropathic pain remain uncertain. We investigated the effects of early TENS (starting from the day after surgery) in mice with neuropathic pain, on hyperalgesia, glial cell activation, pain transmission neuron sensitization, expression of proinflammatory cytokines, and opioid receptors in the spinal dorsal horn. Following nerve injury, TENS and behavioral tests were performed every day. Immunohistochemical, immunoblot, and flow cytometric analysis of the lumbar spinal cord were performed after 8 days. Early TENS reduced mechanical and thermal hyperalgesia and decreased the activation of microglia and astrocytes (P<0.05). In contrast, the application of TENS at 1 week (TENS-1w) or 2 weeks (TENS-2w) after injury was ineffective in reducing hyperalgesia (mechanical and thermal) or activation of microglia and astrocytes. Early TENS decreased p-p38 within microglia (P<0.05), the expression levels of protein kinase C (PKC-γ), and phosphorylated anti-phospho-cyclic AMP response element-binding protein (p-CREB) in the superficial spinal dorsal horn neurons (P<0.05), mitogen-activated protein (MAP) kinases, and proinflammatory cytokines, and increased the expression levels of opioid receptors (P<0.05). The results suggested that the application of early TENS relieved hyperalgesia in our mouse model of neuropathic pain by inhibiting glial activation, MAP kinase activation, PKC-γ, and p-CREB expression, and proinflammatory cytokines expression, as well as maintenance of spinal opioid receptors. The findings indicate that TENS treatment is more effective when applied as early after nerve injury as possible.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

B9285
5-Bromo-2′-deoxyuridine, BioUltra, ≥99%
C9H11BrN2O5
AV40173
Anti-ACTB antibody produced in rabbit, affinity isolated antibody, lyophilized powder
SAB2100037
Anti-ACTB antibody produced in rabbit, affinity isolated antibody
SAB3500350
Anti-β-Actin antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB1400139
Anti-IL6 antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution
SAB1408591
Anti-IL6 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
GW22495
Anti-Interleukin-6 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
I2143 Anti-Interleukin-6 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB4502982
Anti-TNFA antibody produced in rabbit, affinity isolated antibody
T0813 Anti-Tumor Necrosis Factor-α antibody produced in goat, affinity isolated antibody, lyophilized powder
T1816 Anti-Tumor Necrosis Factor-α antibody produced in goat, affinity isolated antibody, lyophilized powder
T0938 Anti-Tumor Necrosis Factor-α antibody produced in goat, affinity isolated antibody, lyophilized powder
T8300
Anti-Tumor Necrosis Factor-α antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
WH0000060M1
Monoclonal Anti-ACTB antibody produced in mouse, clone 3G4-F9, purified immunoglobulin, buffered aqueous solution
SAB1403520
Monoclonal Anti-ACTB antibody produced in mouse, clone 1E7, purified immunoglobulin, buffered aqueous solution
WH0003569M1
Monoclonal Anti-IL6 antibody produced in mouse, clone 3E4, purified immunoglobulin, buffered aqueous solution
SAB1400140
Monoclonal Anti-IL6 antibody produced in mouse, clone 2D12, purified immunoglobulin, buffered aqueous solution
SAB5300275
Monoclonal Anti-IL6 antibody produced in mouse, clone 6D9A1, ascites fluid
I7901 Monoclonal Anti-Interleukin-6 antibody produced in mouse, clone 6708.11, purified immunoglobulin, lyophilized powder
WH0007124M2
Monoclonal Anti-TNF antibody produced in mouse, clone 1C3-A1-F4, purified immunoglobulin, buffered aqueous solution
SAB1404480
Monoclonal Anti-TNF antibody produced in mouse, clone M1-C4, purified immunoglobulin, buffered aqueous solution
T3198 Monoclonal Anti-Tumor Necrosis Factor-α antibody produced in mouse, clone 45418.111, purified immunoglobulin, lyophilized powder
T6817 Monoclonal Anti-Tumor Necrosis Factor-α antibody produced in mouse, clone 28401, purified immunoglobulin, lyophilized powder